BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Pancreatic cancer AND NRG1, ENSG00000157168, 3084, SMDF, NDF, HRGA, HRG1, HGL, GGF2, GGF, ARIA
44 results:

  • 1. pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
    Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
    Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Real-world outcomes associated with afatinib use in patients with solid tumors harboring nrg1 gene fusions.
    Liu SV; Frohn C; Minasi L; Fernamberg K; Klink AJ; Gajra A; Savill KMZ; Jonna S
    Lung Cancer; 2024 Feb; 188():107469. PubMed ID: 38219288
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. pancreatic cancer Action Network's SPARK: A Cloud-Based Patient Health Data and Analytics Platform for pancreatic cancer.
    Abdilleh K; Khalid O; Ladnier D; Wan W; Seepo S; Rupp G; Corelj V; Worman ZF; Sain D; DiGiovanna J; Press B; Chandrashekhar S; Collisson E; Cui KY; Maitra A; Rejto PA; White KP; Matrisian L; Doss S
    JCO Clin Cancer Inform; 2024 Jan; 8():e2300119. PubMed ID: 38166233
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset pancreatic cancer.
    Ogobuiro I; Baca Y; Ribeiro JR; Walker P; Wilson GC; Gulhati P; Marshall JL; Shroff RT; Spetzler D; Oberley MJ; Abbott DE; Kim HJ; Kooby DA; Maithel SK; Ahmad SA; Merchant NB; Xiu J; Hosein PJ; Datta J
    JCO Precis Oncol; 2023 Sep; 7():e2300152. PubMed ID: 37944072
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. The marine Penicillium sp. ggf16-1-2 metabolite dicitrinone G inhibits pancreatic angiogenesis by regulating the activation of NLRP3 inflammasome.
    Shi Z; Zhang M; Fan H; Chen Y; Dong S; Zhou F; Wang B; Liu J; Jin J; Luo Y; Chen Q; Wang W; Zhang C; Chen Y
    J Nat Med; 2024 Jan; 78(1):78-90. PubMed ID: 37897512
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Stromal-derived nrg1 enables oncogenic KRAS bypass in pancreas cancer.
    Han J; Xu J; Liu Y; Liang S; LaBella KA; Chakravarti D; Spring DJ; Xia Y; DePinho RA
    Genes Dev; 2023 Sep; 37(17-18):818-828. PubMed ID: 37775182
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. RNA Sequencing Identifies Novel nrg1 Fusions in Solid Tumors that Lack Co-Occurring Oncogenic Drivers.
    Severson E; Achyut BR; Nesline M; Pabla S; Previs RA; Kannan G; Chenn A; Zhang S; Klein R; Conroy J; Sausen M; Sathyan P; Saini KS; Ghosh A; Jensen TJ; Reddy P; Ramkissoon SH
    J Mol Diagn; 2023 Jul; 25(7):454-466. PubMed ID: 37164276
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.
    Desai O; Wang R
    Oncotarget; 2023 May; 14():439-443. PubMed ID: 37163206
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. PARPis and Other Novel, Targeted Therapeutics in pancreatic Adenocarcinoma.
    Chapin WJ; Reiss KA
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):1019-1032. PubMed ID: 36154785
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Rare Carbon-Bridged Citrinin Dimers from the Starfish-Derived Symbiotic Fungus
    Fan H; Shi ZM; Lei YH; Si-Tu MX; Zhou FG; Feng C; Wei X; Shao XH; Chen Y; Zhang CX
    Mar Drugs; 2022 Jul; 20(7):. PubMed ID: 35877736
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Molecular Characterization of KRAS Wild-type Tumors in Patients with pancreatic Adenocarcinoma.
    Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
    Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. CD74-nrg1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.
    Werr L; Plenker D; Dammert MA; Lorenz C; Brägelmann J; Tumbrink HL; Klein S; Schmitt A; Büttner R; Persigehl T; Shokat KM; Wunderlich FT; Schram AM; Peifer M; Sos ML; Reinhardt HC; Thomas RK
    Mol Cancer Ther; 2022 May; 21(5):821-830. PubMed ID: 35247925
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by nrg1 Gene Rearrangements.
    Schram AM; Odintsov I; Espinosa-Cotton M; Khodos I; Sisso WJ; Mattar MS; Lui AJW; Vojnic M; Shameem SH; Chauhan T; Torrisi J; Ford J; O'Connor MN; Geuijen CAW; Schackmann RCJ; Lammerts van Bueren JJ; Wasserman E; de Stanchina E; O'Reilly EM; Ladanyi M; Drilon A; Somwar R
    Cancer Discov; 2022 May; 12(5):1233-1247. PubMed ID: 35135829
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy.
    Diamond JR; Boni V; Lim E; Nowakowski G; Cordoba R; Morillo D; Valencia R; Genvresse I; Merz C; Boix O; Frigault MM; Greer JM; Hamdy AM; Huang X; Izumi R; Wong H; Moreno V
    Clin Cancer Res; 2022 Apr; 28(7):1285-1293. PubMed ID: 35046056
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The potential targeted drugs for fusion genes including nrg1 in pancreatic cancer.
    Umemoto K; Sunakawa Y
    Crit Rev Oncol Hematol; 2021 Oct; 166():103465. PubMed ID: 34454058
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. [Ductal adenocarcinoma of the pancreas: subtypes and molecular pathology].
    Schlitter AM; Konukiewitz B; Kasajima A; Reichert M; Klöppel G
    Pathologe; 2021 Sep; 42(5):464-471. PubMed ID: 34402977
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Glycemic Changes and Weight Loss Precede pancreatic Ductal Adenocarcinoma by up to 3 Years in a Diverse Population.
    Brewer MJ; Doucette JT; Bar-Mashiah A; Glickman JW; Kessel E; Aronson A; Lucas AL
    Clin Gastroenterol Hepatol; 2022 May; 20(5):1105-1111.e2. PubMed ID: 34358720
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. The pancreatic cancer genome revisited.
    Hayashi A; Hong J; Iacobuzio-Donahue CA
    Nat Rev Gastroenterol Hepatol; 2021 Jul; 18(7):469-481. PubMed ID: 34089011
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Early-Onset Pancreas cancer: Clinical Descriptors, Genomics, and Outcomes.
    Varghese AM; Singh I; Singh R; Kunte S; Chou JF; Capanu M; Wong W; Lowery MA; Stadler ZK; Salo-Mullen E; Saadat LV; Wei AC; Reyngold M; Basturk O; Benayed R; Mandelker D; Iacobuzio-Donahue CA; Kelsen DP; Park W; Yu KH; O'Reilly EM
    J Natl Cancer Inst; 2021 Sep; 113(9):1194-1202. PubMed ID: 33755158
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Identification of tumors with nrg1 rearrangement, including a novel putative pathogenic UNC5D-nrg1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
    Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
    Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.